News archive.
Earlier AI news and analysis, kept for reference. Current coverage lives in News & Analysis.
Google: Chinese hackers hit U.S. and Canadian research labs for a year
Google's Threat Analysis Group reports a sustained campaign targeting government and academic institutions. The group used custom malware and zero-day exploits to steal research data.
OpenAI spent $34B last year, IPO on deck
OpenAI's annual spending reached $34 billion in 2024, per Financial Times reporting. The company is preparing for a public offering that could reshape AI funding dynamics.
Judge dismisses Musk's xAI trade secret suit against OpenAI
A US judge has thrown out Elon Musk's lawsuit alleging OpenAI stole trade secrets for xAI. The dismissal narrows what legal claims can survive against the AI company.
US blocks Anthropic's Claude Fable 5 over security fears
Days after launch, the US government forced Anthropic to disable Claude Fable 5 and Mythos 5 for all users citing national security. Legal teams relying on single-model strategies now face supply chain risk.
Law Firms Need AI Governance, Not Just AI Tools
Legal IT Insider's third annual report on generative AI in law finds that firms treating AI as a compliance problem miss the real issue: governance is now the infrastructure that makes supervised AI work defensible in court.
AI Drug Discovery Hits Biology, Not Model, Limits
The real bottleneck in computational drug discovery isn't algorithmic—it's the quality and completeness of biological data. Teams are discovering that better models can't compensate for gaps in experimental validation.
Olin and Huntsman Merge to Form $12B North American Chemical Company
Olin Corporation and Huntsman Corporation announced a merger creating a $12+ billion chemicals producer focused on North American operations. The deal combines two major industrial chemical makers into a single integrated platform.
U.S. News releases 2026-2027 global universities ranking
U.S. News & World Report published its latest global university rankings. See which institutions moved and how the methodology evolved.
IDEAYA starts Phase 1/2 trial of IDE892 in MTAP-deleted cancers
IDEAYA Biosciences initiated clinical testing of IDE892, a PRMT5 inhibitor designed for pancreatic and lung cancers with MTAP deletions. The compound targets a genetic vulnerability present in a subset of patients.
Genmab's Epkinly Cuts Lymphoma Relapse Risk by 26% but Misses Survival Goal
Phase III EPCORE DLBCL-1 trial met progression-free survival endpoint (HR 0.74) in transplant-ineligible patients but failed to show overall survival benefit. FDA approval now uncertain amid stricter OS guidance.
ALK wins UK approval for needle-free adrenaline auto-injector for children
ALK's EURneffy 1mg received MHRA marketing authorisation as a needle-free treatment for paediatric anaphylaxis. What the approval means for emergency care delivery and device adoption.
Alkermes wins FDA orphan drug status for narcolepsy treatment alixorexton
Alkermes secured orphan designations from the FDA and European Commission for alixorexton, an orexin receptor agonist in Phase III trials for narcolepsy and idiopathic hypersomnia. The status unlocks seven to ten years of market exclusivity.